Gastrointestinal tumours
What is the interventional treatment in HCC?
Date
20 Dec 2015Session
Gastrointestinal tumoursPresenters
Pierce ChowAuthors
P. ChowAuthor affiliations
- National Cancer Center Singapore, Singapore/SG
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
317 - Ginsenoside Rg3 improves transarterial chemoembolization treatment in Chinese patients with advanced hepatocellular carcinoma
Presenter: BO Zhou
Session: Gastrointestinal tumours
Resources:
Abstract
434 - TACE with sorafenib for recurrent hepatocellular carcinoma: a retrospective nested case-control study
Presenter: Xuying Wan
Session: Gastrointestinal tumours
Resources:
Abstract
1340 - Pattern of regional recurrence after curative resection in adenocarcinoma of oesophagogastric junction: Implication for elective lymphatic target definition of radiotherapy
Presenter: Jiajia Zhang
Session: Gastrointestinal tumours
Resources:
Abstract
758 - Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI + cetuximab every other week in the APEC study
Presenter: Ann-Lii Cheng
Session: Gastrointestinal tumours
Resources:
Abstract
1041 - Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases
Presenter: KIN SANG Lau
Session: Gastrointestinal tumours
Resources:
Abstract
Invited discussant abstracts 146PD and 147PD
Presenter: Pierce Chow
Session: Gastrointestinal tumours
Resources:
Slides
Webcast
How can we predict success in anti-EGFR?
Presenter: Eric van Cutsem
Session: Gastrointestinal tumours
Resources:
Slides
Webcast
Invited discussant abstracts 148PD, 149PD and 150PD
Presenter: Jean-Yves Douillard
Session: Gastrointestinal tumours
Resources:
Slides
Webcast